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Introduction: The blood–brain barrier (BBB) protects the brain against potentially neurotoxic molecules in the
circulation, and loss of its integrity may contribute to disease progression in neurodegenerative conditions. Recently,
the active role of reactive astrocytes in BBB disruption has become evident in the inflamed brain. In the present study,
we investigated whether mesenchymal stem cell (MSC) treatment might modulate reactive astrocytes and thus
stabilize BBB integrity through vascular endothelial growth factor A (VEGF-A) signaling in inflammatory conditions.
Methods: For the inflamed brain, we injected LPS using a stereotaxic apparatus and MSCs were injected into the tail
vein. At 6 hours and 7 days after LPS injection, we analyzed modulatory effects of MSCs on the change of BBB
permeability through VEGF-A signaling using immunochemistry and western blot. To determine the effects of MSCs on
VEGF-A-related signaling in cellular system, we had used endothelial cells treated with VEGF-A and co-cultured astrocyte
and BV 2 cells treated with lipopolysaccharide (LPS) and then these cells were co-cultured with MSCs.
Results: In LPS-treated rats, MSCs restored Evans blue infiltration and the number of endothelial-barrier antigen (EBA)
and P-glycoprotein (p-gp)-expressing cells, which were significantly altered in LPS-treated animals. Additionally, MSC
administration following LPS treatment markedly increased the density of astrocytic filaments around vessels and
reversed LPS-induced elevations in VEGF-A levels as well as endothelial nitric oxide synthase (eNOS)-dependent
downregulation of tight junction proteins in the endothelium. Consequently, MSC treatment reduced neutrophil
infiltration and enhanced survival of midbrain dopaminergic neurons in LPS-treated animals. In cellular system, MSC
treatment led to a significant reversion of VEGF-A-induced eNOS and tight junction protein expression in endothelial
cells, which led to increased EBA expressing cells. Additionally, MSC treatment significantly attenuated LPS-induced
increased expressions of IL-1β in microglia and VEGF-A in astrocytes with an increase in IL-10 levels.
Conclusion: The present study indicated that MSCs may stabilize BBB permeability by modulating astrocytic endfeet
and VEGF-A signaling, which may be relevant to the treatment of Parkinsonian diseases as a candidate for disease
modifying therapeutics.Introduction
The blood–brain barrier (BBB) tightly regulates ion bal-
ance and nutrient transport, and acts as a protective bar-
rier to shield the central nervous system from potentially
neurotoxic molecules in the circulation. The integrity of
the BBB is altered in neurodegenerative diseases such as
Alzheimer’s disease and Parkinson’s disease (PD), and
seems to be influenced by disease severity and duration* Correspondence: phisland@chol.net
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progression in neurodegenerative conditions, although the
underlying mechanism has not been elucidated fully.
Astrocytes, the most abundant cells in the brain,
contact the brain vasculature via their endfeet pro-
cesses. These contacts consist of endothelial tight junc-
tions, which probably prevent diffusion of toxic
materials across the BBB [3]. However, reactive astro-
cytes in the inflamed brain retract their endfeet from
vessels, increasing BBB permeability, and proliferate,
giving rise to glial scars [4–6]. Furthermore, reactive as-
trocytes secrete increased levels of the proangiogenic
vascular endothelial growth factor A (VEGF-A) more
than basal levels in normal physiological conditions.distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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inflammation-induced expression of VEGF-A induces BBB
breakdown and immune cell infiltration through disrupted
tight junctions, accompanied by altered expression of the
tight junction proteins [7–9]. The downstream cascade
appears to be mediated by endothelial nitric oxide syn-
thase (eNOS); systemic administration of a selective
eNOS inhibitor abrogates VEGF-A-induced BBB dis-
ruption and protects against neurologic deficits in
models of inflammatory disease [9]. Blockade of VEGF-
A signaling may therefore be a viable strategy to pre-
serve BBB integrity in neurodegenerative diseases.
Previously, we demonstrated that mesenchymal stem
cells (MSCs) protect dopaminergic neurons through
anti-inflammatory properties mediated by modulation
of microglial activation in animal models of PD [10, 11].
Additionally, in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyri-
dine (MPTP)-induced PD, Chao et al. [12] reported re-
cently that this effect promoted recovery of BBB integrity.
In the present study, we investigated whether MSC treat-
ment might modulate reactive astrocytes and thus stabilize
BBB integrity through VEGF-A signaling pathways in both
cellular and animal models of inflammatory conditions.Materials and methods
Antibodies
Antibodies and staining reagents included mouse anti-
tyrosine hydroxylase (TH; 1:2000 dilution for brain
tissue, dopaminergic neuron marker, Pel-Freez, Rogers,
AR, USA) and rabbit anti-ionized calcium-binding
adapter molecule 1 (Iba-1; 1:1000 dilution, activated
microglia marker, Wako, Osaka, Japan) anti-GFAP
(1:1000 dilution, astrocyte marker, Chemicon, Darmstadt,
Germany), anti-myeloperoxidase (MPO; 1:1000 dilution,
neutrophil marker, Dako, Glostrup, Denmark), anti-endo-
thelial barrier antigen (EBA; 1:1000 dilution, endothelial
cell marker, Sternberger Monoclonals, Lutherville, MD,
USA), anti-P-glycoprotein (P-gp; 1:5000 dilution, membra-
netransporter marker, Becton Dickinson, USA), anti-clau-
din-5 (CLN-5; 1:500 dilution, tight junction protein
marker, Invitrogen, Waltham, MA, USA), anti-endothelial
nitric oxide synthase (eNOS, 1:2500 dilution, BD Bio-
science, Mississauga, ON, Canada), anti-IL-10 (1:200
dilution, anti-inflammatory marker, Santa Cruz, Santa
Cruz, CA, USA), anti-IL-1b (1:200 dilution, inflamma-
tory marker, Santa Cruz), anti-CD 31(1:200 dilution,
endothelial cell marker, Nouves), anti- aquaporin 4
(AQP-4; 1:50 dilution, astrocyte endfeet marker, Santa
Cruz, Santa Cruz, CA, USA) and mouse anti-nuclear
mitotic apparatus protein (NuMA, 1:100 dilution;
Calbiochem, San Diego, CA, USA), as well as FITC-
labeled tomato lectin (1:1000; Vector Laboratories,
Burlingame, CA, USA).Animal studies
Male Sprague–Dawley rats (250–270 g) were anesthetized
with 10 % chloral hydrate prior to lipopolysaccharide
(LPS) injection. LPS (5 μg dissolved in 3 μl) was delivered
unilaterally into the left substantia nigra (SN; 5.3 mm pos-
terior, 2.3 mm lateral, 7.7 mm ventral from the bregma)
and injected at a rate of 0.2 μl/minute using a 26-gauge
Hamilton syringe attached to an automated microinjector
using a stereotaxic apparatus [13]. The needle was then
left in place for an additional 10 minutes before slow re-
traction. The control group was injected with phosphate-
buffered saline (PBS; 3 μl) at the same position and using
the same method. At 4 hours after LPS injection, MSCs
(1 × 106 cells in 200 μl) were injected into the tail vein
[11]. For tissue preparation, rats were sacrificed at 6 hours,
12 hours, 1 day, 2 days, and 7 days after the LPS injection
[14]. Histopathological samples from three groups of
rats (control, LPS only, MSC treatment following LPS)
were compared. The animal work was approved by the
Institutional Animal Care and Use Committee of Yonsei
University (approval number: 2013–0379).
Isolation of MSCs
Bone marrow aspirates (10 ml) were obtained from the iliac
crests of human donors. The mononuclear cell layer was
isolated by Ficoll–Hypaque, washed in PBS, plated in poly-
styrene plastic 100 mm culture dishes, and cultivated in
low-glucose Dulbecco’s modified Eagle’s medium (DMEM;
Gibco-BRL, Grand Island, NY, USA) containing 10 % fetal
bovine serum (FBS; Hyclone, Irvine, CA, USA) and 1 %
penicillin/streptomycin (Sigma, St. Louis, MO, USA) in a
humidified incubator at 37 °C under 5 % CO2. Nonadher-
ent cells were removed after 24 hours. When these primary
cultures reached 80 % confluence, the cells were harvested
using 0.25 % trypsin and subcultured. At passage 6, MSCs
were injected into the tail vein or cultured in individual
wells of 24-transwell plates (3 × 103 cells/transwell) or
six-transwell plates (3 × 104 cells/transwell) 1 day be-
fore the experiment. The study protocol and consent
form were approved by the Institutional Review Board
for Human Investigation of Yonsei University Sever-
ance Hospital.
Extravasation of Evans blue dye
To measure the vascular permeability in the brain, Evans
blue dye (EB, 4 % in saline, 3 ml/kg) was intravenously
injected. Fifteen minutes later, the rats were anesthetized
and perfused. The frozen sections were prepared, and the
infiltrated EB was analyzed using a confocal microscope
(Carl Zeiss, Oberkochen, Germany).
Tissue preparation
For immunohistochemistry, rats were perfused with saline
solution containing 0.5 % sodium nitrate and heparin (10
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0.1 M PBS (~150 ml/rat) at 12 hours and 7 days after the
first drug injection. Brains were removed and post-fixed
overnight in buffered 4 % paraformaldehyde at 4 °C and
stored in a 30 % sucrose solution for 1–2 days at 4 °C until
they sank. The brains were then sectioned into 30 μm cor-
onal slices, which were stored in tissue stock solution (30 %
glycerol, 30 % ethylene glycol, 30 % three-times distilled
water, 10 % 0.2 M phosphate buffer (PB)) at 4 °C until re-
quired. For western blotting, rats were euthanized at
12 hours after the first injection, and the SN were rapidly
dissected and frozen at −70 °C. For enzyme-linked immuno-
sorbent assay (ELISA), rats were euthanized at 6 hours,
12 hours, 1 day, 2 days, and 7 days after first injection, and
the SN were rapidly dissected and frozen at −70 °C.
Immunohistochemistry and immunocytochemistry
Coronal brain sections and cocultured bEnd.3 cells were
rinsed twice in PBS, incubated in 0.2 % Triton X-100 for
30 minutes at room temperature, and rinsed three times
with 0.5 % bovine serum albumin (BSA) in 1× PBS for
blocking. After blocking, they were incubated overnight
at 4 °C with primary antibody (anti-TH, anti-P-gp, anti-
MPO, or anti-EBA), rinsed three times in 1× PBS con-
taining 0.5 % BSA (10 minutes/rinse), and incubated
with the appropriate biotinylated secondary antibody
and avidin–biotin complex (Elite Kit; Vector Laboratories,
Burlingame, CA, USA) for 1 hour at room temperature.
Bound antibodies were visualized by incubating with
0.05 % diaminobenzidine–HCl (DAB) and 0.003 % hydro-
gen peroxide in 1× PBS. Brain sections were rinsed with
1× PBS for DAB inhibition. Immunostained cells were an-
alyzed by bright-field microscopy.
Immunofluorescence
Expression of Iba-1, eNOS, CD31, GFAP, AQP-4, IL-10,
IL-1β, and CLN-5 was assessed using fluorescently
tagged secondary antibodies. Brain sections and cocul-
tured bEnd.3 cells were treated as already described, ex-
cept that secondary antibodies included goat anti-mouse
IgG (Alexa Fluor-488, green) and goat anti-rabbit IgG
(Alexa Fluor-594, red). For tomato lectin (TL) label-
ing, sections were incubated with Alexa Fluor-594-
conjugated secondary antibodies and FITC-labeled TL
for 1 hour. Following secondary antibody incubation,
samples were washed and mounted using a Prolong Anti-
fade Kit (Molecular Probes, Waltham, MA, USA). Stained
cells and tissues were viewed using an Olympus I × 71 con-
focal laser scanning microscope (Olympus, Tokyo, Japan).
bEnd.3 cell culture
bEnd.3 cells (endothelial cell lines; ATCC, University Boule-
vard Manassas, VA, USA) were maintained in DMEM sup-
plemented with 10 % FBS. Cells were cultured in 25 cm2flasks and routinely passaged using trypsin–ethylenediamine
tetraacetic acid (EDTA) solution. Cells were subcultured into
individual wells of 24-well plates (1 × 105 cells/well) or six-
well plates (1 × 106 cells/well) 1 day before the experiment.
Primary astrocyte culture
Astrocyte was cultured from the cerebral cortices of
mouse pups. The cortices were rinsed twice in minimum
essential medium (MEM; Sigma) containing 10 % FBS and
triturated mechanically. The dissociated cells were plated
with 75 cm2 T-flasks. After 2 weeks, the astrocyte was
detached from the flasks, and seeded onto 24-well plates
(1 × 105 cells/well) or six-well plates (1 × 106 cells/well).
After 30 minutes to 1 hour, the culture medium was re-
placed with MEM containing 5 % FBS.
BV 2 cell culture
BV 2 cells (microglia lines; ATCC) were maintained in
DMEM supplemented with 10 % FBS. Cells were cul-
tured in 25 cm2 flasks and routinely passaged using
trypsin–EDTA solution. Cells were cocultured into in-
dividual wells of 24-well plates (5 × 104 cells/well) or
six-well plates (5 × 105 cells/well) in seeded astrocytes.
VEGF-A or LPS treatment and coculture with MSCs
Seeded bEnd.3 cells were treated with VEGF-A (10 ng/ml;
R&D systems, Minneapolis, MN, USA) in a humidified
incubator at 37 °C for 24 hours. MSCs (3 × 104 cells/well
in 24-well plate or 3 × 105 cells/well in six-well plate) in
transwells (0.4 μm pore size; Corning, N.Y.C, NY, USA)
were then placed in each well and incubated for another
24 hours. Cocultured astrocytes and BV 2 cells were
treated with LPS (100 ng/ml; Sigma, Dorset, SP, USA) for
4 hours in a humidified incubator at 37 °C. MSCs (3 × 104
cells/well in 24-well plate or 3 × 105 cells/well in six-well
plate) in transwells were then placed in each well and incu-
bated for another 24 hours.
Western blot analysis
Cocultured bEnd.3 cells were dissolved in ice-cold lysis buf-
fer (20 mM Tris–HCl, pH 7.5, 1 mM EDTA, 5 mM MgCl2,
1 mM dithiothreitol, 0.1 mM phenylmethylsulfonyl fluoride
plus protease inhibitor cocktail; Sigma). Lysates were cen-
trifuged (20 minutes, 14,000 × g, 4 °C) and supernatants
were transferred to fresh tubes. Proteins were analyzed
using the Bio-Rad Protein Assay Kit (Bio-Rad, Hercules,
CA, USA). Equal amounts of protein (20–50 μg) were
loaded in each lane with loading buffer containing 0.125 M
Tris–HCl, pH 6.8, 20 % glycerol, 4 % sodium dodecyl sul-
fate, 10 % mercaptoethanol, and 0.002 % bromophenol
blue. Samples were boiled for 5 minutes before gel loading.
Separated proteins were electrophoretically transferred to
polyvinylidene difluoride membranes (Millipore, Bedford,
MA, USA). Membranes were washed in Tris-buffered
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blocked in TNE containing 5 % skim milk for 1 hour.
Membranes were incubated overnight at 4 °C with primary
antibodies (CLN-5, eNOS, IL-10, IL-1β, VEGF-A) and then
were washed three times. The membranes were incubated
with secondary antibody (1:10,000 dilution of horseradish
peroxidase-conjugated goat anti-rabbit antibody; GenDE-
POT, Barker, TX, USA) and anti-mouse antibody (GenDE-
POT, Barker, TX, USA) for 1 hour at room temperature.
They were developed using ECL western blotting detection
reagent (Amerxham, Pittsburgh, PA, USA), followed by ex-
posure to X-ray film. For semiquantitative analysis, the
density of immunoblot bands was measured using com-
puter imaging (Fujifilm, Tokyo, Japan).
VEGF-A ELISA
VEGF-A levels in SN tissue were measured using a
sandwich ELISA kit according to the manufacturer’s in-
structions (Abnova, Taipei City, Taiwan). To analyze the
changes of VEGF-A levels in the midbrain following
MSC treatment, we measured VEGF-A levels at 6 hours,
12 hours, 1 day, 2 days, and 7 days after LPS injection.
Behavior test
At 1 day and 7 days after LPS injection, apomorphine-
induced (0.5 mg/kg subcutaneously; Sigma) rotation was
assessed for 30 minutes. Only animals showing a mean of
six contralateral rotations/minute over 30 minutes follow-
ing the administration of apomorphine were retained.
Stereological cell counts
Unbiased stereological estimations of the total number of
TH-positive and MPO-positive cells in the SN were made
using an optical fractionator as described previously, with
some modifications [15]. This sampling technique is not
affected by tissue volume changes and does not require
reference volume determinations [16]. The sections used
for counting (eight or nine per series) covered the entire
SN from the rostral tip of the pars compacta to the caudal
end of the pars reticulata. Sampling was performed using
the Olympus CAST-Grid system (Olympus Denmark A/S,
Ballerup, Denmark) in which an Olympus BX51 micro-
scope measured distances on the z axis. The SN was delin-
eated at 1.25× magnification. A counting frame (60 %, 35
units, 650 μm2) was placed randomly on the first counting
area and systematically moved through all counting areas
until the entire delineated area was sampled. Actual
counting was performed using a 40× oil objective. Guard
volumes (4 μm from the top and 4–6 μm from the bottom
of the section) were excluded from both surfaces, and only
profiles that came into focus within the counting volume
(with a depth of 10 μm) were counted. The total number
of stained cells was calculated according to the optical
fractionator formula [16].Statistical analysis
Mann–Whitney and Kruskal–Wallis tests were used
to compare means between groups and for multiple
comparisons, respectively. p <0.05 was considered
statistically significant. Statistical analyses were per-
formed using commercially available software (version
10.0; SPSS, Inc., Chicago, IL, USA).
Results
MSC treatment reduces BBB permeability in LPS-induced
animals
To determine the effects of MSCs on BBB permeability,
brain tissue in the SN was stained with EB, a marker for
BBB permeability, and antibodies against EBA, a marker
of endothelial cells. LPS administration into the SN in-
creased EB infiltration and decreased EBA-positive cells
(Fig. 1a, b); however, MSC treatment following LPS ad-
ministration markedly decreased EB infiltration (Fig. 1a)
and increased EBA-positive cells (Fig. 1b). Stereological
analysis revealed that MSC treatment significantly in-
creased the number of EBA-positive cells in the SN at
12 hours and 7 days after LPS injection relative to LPS-
treated rats (p <0.001; Fig. 1c). In addition, LPS admin-
istration caused a marked increase in P-gp-positive
cells (Fig. 1d); however, MSC treatment following LPS
administration significantly reduced this effect (Fig. 1d).
Quantification confirmed that MSC treatment significantly
decreased P-gp-positive cells in the SN of LPS-treated ani-
mals compared with only LPS-treated animals at 12 hours
and 7 days after LPS injection (Fig. 1e; p <0.001).
MSC treatment enhances filament density in astrocytic
endfeet in LPS-induced animals
The astrocytic endfeet that engulf the capillary networks
of the brain have been assumed to significantly influence
neurovascular structure and integrity. LPS administra-
tion in the SN reduced the density of astrocyte filaments;
however, MSC treatment following LPS administration
markedly increased the astrocytic filament density at
12 hours and 7 days after LPS injection (Fig. 2a). To fur-
ther evaluate astrocytic endfeet around vessels, GFAP
and TL (Fig. 2a) or AQP-4 and CD31 (Fig. 2b) double
staining was performed. Compared with controls, astro-
cytic filaments and endfeet were sparsely distributed in
the SN of LPS-treated animals. On the other hand, MSC
treatment markedly increased the density of astrocytic
filaments around vessels (Fig. 2a) and astrocytic endfeet
(Fig. 2b) in LPS-treated animals. The density of astro-
cytic filaments around vessels at 7 days after LPS in-
jection was decreased compared with the density at
12 hours after LPS injection. However, MSC treatment
increased the density of astrocytic filaments at 7 days after
LPS injection relative to the density at 12 hours after LPS
injection (Fig. 2a, b).
Fig. 2 MSC treatment enhances filament density in astrocytic endfeet in LPS-induced animals. In GFAP and TL a or in AQP-4 and CD31 b double
staining, astrocytic filaments and endfeet were sparsely distributed in the SN of LPS-treated animals. On the other hand, MSC treatment markedly
increased the density of astrocytic filaments around vessels a as well as astrocytic endfeet b in LPS-treated animals. Scale bar: 20 μm. AQP-4 aquaporin
4, DAPI 4',6-diamidino-2-phenylindole, GFAP glial fibrillary acidic protein, LPS lipopolysaccharide, MSC mesenchymal stem cell, TL tomato lectin
Fig. 1 MSC treatment reduces BBB permeability in LPS-induced animals. LPS administration into the SN increased EB infiltration and decreased
EBA-expressing cells; however, MSC treatment following LPS administration markedly decreased EB infiltration a and increased EBA-immunoreactive
cells in the SN b (n = 5). **p <0.01. Scale bar: 20 μm and 100 μm. Number of EBA-positive cells as quantified by stereological analysis c. In addition,
MSC treatment significantly decreased the number of P-gp-expressing cells in the SN of LPS-treated animals compared with only LPS-treated animals
d, e (n = 5). **p <0.01. Scale bar: 100 μm. EBA endothelial-barrier antigen, LPS lipopolysaccharide, MSC mesenchymal stem cell, p-gp P-glycoprotein
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VEGF-A in LPS-induced animals
To evaluate the effects of MSCs on expression of VEGF-A,
we determined VEGF-A levels by ELISA at 6 hours,
12 hours, 1 day, 2 days, and 7 days after LPS injection.
Compared with controls, LPS-treated rats expressed sig-
nificantly greater levels of VEGF-A from 12 hours after
LPS injection, and elevated VEGF-A levels were sustained
7 days after LPS injection. However, MSC treatment sig-
nificantly reduced VEGF-A expression compared with that
in LPS only-treated rats, and these levels were similar to
those in controls (Fig. 3a). Furthermore, we evaluated
whether the effects of MSCs on VEGF-A regulate eNOSFig. 3 MSCs modulate tight junction protein expression via VEGF-A in LPS-indu
increased from 12 hours after LPS injection, and elevated VEGF-A levels were su
attenuated VEGF-A expressions in LPS-treated rats a (n= 3). *p <0.05, **p <0.01.
upregulated eNOS immunoreactivity b and downregulated CLN-5 immun
attenuated eNOS expression and increased CLN-5 expression in the endot
20 μm. CLN-5 claudin-5, DAPI 4',6-diamidino-2-phenylindole, eNOS endoth
stem cell, VEGF vascular endothelial growth factorexpression and tight junction integrity by double immuno-
staining for eNOS and CD31 or CLN-5 and CD31. LPS
treatment markedly upregulated eNOS immunoreactivity
and downregulated CLN-5 immunoreactivity in the endo-
thelial cells of the SN; however, MSC treatment in LPS-
treated animals attenuated eNOS expression and increased
CLN-5 expression in the endothelial cells at 12 hours and
7 days after LPS injection (Fig. 3b, c).
MSC treatment reduces neutrophil infiltration and loss of
dopaminergic cells in the SN
To determine the effects of MSCs on neutrophil infiltra-
tion, SN tissue was immunostained for MPO, a markerced animals. Compared with controls, the VEGF-A levels were significantly
stained 7 days after LPS injection. Meanwhile, MSC treatment significantly
Double immunofluorescence showed that LPS treatment markedly
oreactivity c in the endothelial cells of the SN, whereas MSC treatment
helial cells at 12 hours and 7 days after LPS injection b, c. Scale bar:
elial nitric oxide synthase, LPS lipopolysaccharide, MSC mesenchymal
Fig. 4 (See legend on next page.)
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Fig. 4 MSC treatment reduces LPS-induced neutrophil infiltration and loss of dopaminergic cells in the midbrain. There was a marked increase in
MPO-positive cells in LPS-induced animals; however, MSC treatment following LPS administration notably decreased the number of these cells
a (n = 5). **p <0.001. Scale bar: 100 μm. Consequently, MSC treatment inhibited LPS-induced loss of TH-positive cells in the midbrain b (n = 5).
*p <0.05. Behavioral analysis showed that the number of rotations after apomorphine injection was significantly increased in animals receiving
LPS compared with controls, whereas MSC administration led to a significant reduction of rotation behavior in LPS-treated animals c (n = 5).
**p <0.001. Scale bar: 100 μm. LPS, lipopolysaccharide, MSC mesenchymal stem cell, MPO myeloperoxidase, TH tyrosine hydroxylase
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in MPO-positive cells in LPS-induced animals; however,
MSC treatment following LPS administration notably
decreased these cells (Fig. 4a). Stereological analysis
revealed that the number of neutrophils in the SN was
significantly decreased in MSC-treated rats relative to
those treated only with LPS (p <0.001; Fig. 4a). Conse-
quently, MSC treatment decreased LPS-induced loss of
dopaminergic neurons (Fig. 4b). On stereological ana-
lysis, the number of TH-positive cells in the SN was
significantly increased in MSC-treated rats relative to
that in rats treated only with LPS (p <0.05; Fig. 4b).
Behavioral analysis showed that the number of rotations
after apomorphine injection was significantly increased
in animals receiving LPS compared with controls. How-
ever, MSC administration in LPS-treated animals led to a
significant reduction of rotation behavior at 1 day and
7 days after LPS injection (Fig. 4c). We attempted to iden-
tify MSCs in the MSC-treated animals using human-
specific NuMA immunostaining. The histological analysis
showed that NuMA-positive cells were observed in the
left SN (see Additional file 1).MSCs modulate VEGF-A-regulated tight junction protein
expression in bEnd.3 cells
To determine the effects of MSCs on VEGF-A-related
signaling in a cellular system, endothelial cells were
treated with VEGF-A and then co-cultured with MSCs.
Western blots revealed that VEGF-A treatment signifi-
cantly increased eNOS expression and decreased CLN-5
expression in bEnd.3 cells; however, the expressions of
these proteins were reverted to control levels after MSC
treatment (Fig. 5a). This result was further confirmed by
immunocytochemical analysis, which showed that MSC
treatment attenuated VEGF-A-induced increases in
eNOS immunoreactivity and downregulation of CLN-5
immunoreactivity (Fig. 5b, c). Additionally, we assessed
survival of endothelial cells after VEGF-A treatment
using EBA immunocytochemistry. Whereas VEGF-A
treatment decreased EBA immunoreactivity, MSC treat-
ment in these cells markedly increased EBA-positive
cells (Fig. 5d). Stereological analysis revealed that the
number of detected EBA-positive cells was significantly
increased in MSC-treated cells relative to those treated
only with VEGF-A (p <0.001; Fig. 5d).MSCs modulate VEGF-A through anti-inflammatory action
of microglia
To determine the effects of MSCs on the modulation of
VEGF-A in the cellular inflammation system, cocultured
astrocyte and BV 2 cells were treated with LPS and then
cocultured with MSCs. Western blots revealed that LPS
treatment significantly increased IL-1β expression in BV
2 cells and VEGF-A expression in astrocytes; however,
the expressions of these proteins were reverted to con-
trol levels after MSC treatment (Fig. 6a). In addition, IL-
10 levels in cocultured astrocytes and BV 2 cells were
significantly increased after MSC treatment (Fig. 6a).
This result was further confirmed by immunofluores-
cence analysis, demonstrating that MSC treatment atten-
uated LPS-induced increases in immunoreactivities of
IL-1β and VEGF-A (Fig. 6b, c).
Discussion
The present study demonstrates that MSC treatment sig-
nificantly increases survival of dopaminergic neurons by
stabilizing BBB permeability and attenuating neutrophil
infiltration in the SN of LPS-injected animals. Further-
more, we found that MSC treatment restores astrocytic
endfeet and inhibits VEGF-A-related eNOS-dependent
downregulation of CLN-5 in the inflammatory conditions
of cellular and animal models. The present data there-
fore suggest that modulation of astrocytic endfeet and
astrocyte-related angiogenic factors by MSCs may rep-
resent a therapeutic strategy to stabilize BBB integrity
in neurodegenerative conditions.
Ample evidence has suggested that a microglial reaction
and inflammatory processes contribute to the cascade of
neuronal degeneration in neurodegenerative disease [17].
Like other central nervous system diseases such as multiple
sclerosis, brain cancer, or stroke, neuroinflammation is the
main contributor to BBB dysfunction in neurodegenerative
conditions [1, 18–20]. Several clinical studies have demon-
strated BBB dysfunction in patients with neurodegenera-
tive diseases; Skoog et al. [21] identified BBB alterations
before the onset of clinical dementia in AD patients, and
Kortekaas et al. [22] reported BBB impairments in re-
stricted areas of the midbrain in patients with late-stage
PD. Regarding the functional significance of BBB dysfunc-
tions, baseline BBB integrity was closely coupled with
changes in neurological deficits in patients with multiple
system atrophy [23]. Furthermore, in a longitudinal study
Fig. 5 (See legend on next page.)
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Fig. 5 MSCs modulate VEGF-A-regulated tight junction protein expression in bEnd.3 cells. Western blots revealed that VEGF-A treatment significantly
increased eNOS expression and decreased CLN-5 expression in bEnd.3 cells; however, the expressions of these proteins were reverted to control levels
after MSC treatment a (n = 3). *p <0.05, **p <0.01. Immunocytochemical analysis showed that MSC treatment attenuated VEGF-A-induced increases in
eNOS immunoreactivity and downregulation of CLN-5 immunoreactivity b, c. Scale bar: 20 μm. In addition, the number of detected EBA-expressing
cells was significantly increased in MSC-treated cells relative to those treated only with VEGF-A d, e (n = 3). ***p <0.001. Scale bar: 100 μm. CLN-5
claudin-5, DAPI 4',6-diamidino-2-phenylindole, EBA endothelial-barrier antigen, eNOS endothelial nitric oxide synthase, LPS lipopolysaccharide, MSC
mesenchymal stem cell, VEGF vascular endothelial growth factor
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strated that changes in BBB integrity may be a more
reliable biological marker for disease progression in neu-
rodegenerative disease than is baseline BBB status [24].
Collectively, these in vivo data suggest that BBB integrity
might modify disease progression in neurodegenerative
diseases, and thus modulation of BBB integrity could be a
potential treatment for neurodegenerative diseases.Fig. 6 MSCs modulate VEGF-A through anti-inflammatory action of microglia
increased IL-1β expression in BV 2 cells and VEGF-A expression in astrocytes. H
proteins with an increase in IL-10 levels a (n = 3). *p <0.05, **p <0.01. Immuno
increased in immunoreactivities of IL-1β in BV 2 cells b and VEGF-A in astrocyte
acidic protein, IL interleukin, LPS lipopolysaccharide, MSC mesenchymal stem ceThe present study demonstrated that MSCs stabilized
BBB alterations induced by LPS administration into the
SN of rats. MSC treatment significantly restored the ex-
pression of EBA and P-gp in endothelial cells, which
were significantly altered in LPS-treated animals. Conse-
quently, MSC treatment stabilized infiltrations of EB and
activated neutrophils, and thus increased the survival of
dopaminergic neurons in the midbrain of LPS-treated. Using coculture of astrocyte and BV 2 cells, LPS treatment significantly
owever, MSC treatment significantly decreased the expressions of these
fluorescence analysis showed that MSC treatment attenuated LPS-induced
s c. Scale bar: 20 μm. DAPI 4',6-diamidino-2-phenylindole, GFAP glial fibrillary
ll, VEGF vascular endothelial growth factor
Park et al. Stem Cell Research & Therapy  (2015) 6:187 Page 11 of 12rats. We focused our investigation on the mechanism by
which MSCs modulate BBB integrity on astrocytic end-
feet and astrocyte-related angiogenic factors. Astrocytes
are known to be more resistant than neurons to oxida-
tive stress [25], and they are neuroprotective because
they take up potassium and glutamate and release mito-
genic factors [26]. However, in the inflamed brain, astro-
cytes retract their endfeet from vessels, increasing BBB
permeability [4–6]. More importantly, several studies
have documented that expression of the angiogenic fac-
tor VEGF-A by astrocytes is increased by microglia-
induced inflammatory factor IL-1β in the inflamed brain
[7, 27, 28]. In turn, VEGF-A released from astrocytes binds
to VEGF receptor 2 on microvascular endothelial cells and
activates eNOS to downregulate expression of tight junc-
tion proteins, which may lead to disruption of endothelial
tight junctions and increased BBB permeability [7, 9].
Interestingly, the mechanism by which MSCs stabilize
the BBB through astrocytes seems to be complex. First,
our study demonstrated that MSCs can restore the dens-
ity of filaments within astrocytic endfeet surrounding
microvessels. As astrocytic endfeet are a major compo-
nent of the BBB, a lower density of astrocytic filaments
in the midbrain is known to reduce BBB integrity in
LPS-induced models of PD [29]. Restoration of astro-
cytic endfeet by MSCs may thus represent a morpho-
logically stabilizing effect on BBB integrity. Second, the
present study indicates that MSCs may modulate VEGF-
A-related eNOS-dependent downregulation of tight
junction proteins in the endothelium. In LPS-treated
rats, MSC treatment decreased LPS-induced elevation of
VEGF-A levels and downregulation of CLN-5. In
cultured endothelial cells, employed to directly evaluate
modulatory effects of MSCs on VEGF-A-related eNOS-
dependent signaling, MSC treatment reduced VEGF-A-
induced increases in eNOS expression and decreases in
CLN-5 expression, which consequently led to increased
survival of endothelial cells. Regarding the underlying
mechanisms of VEGF-A-related eNOS-dependent sig-
naling by MSCs, inflammatory cytokine IL-1β released
by activated microglia would trigger this signaling path-
way by binding to its receptor on the astrocyte [9]. Our
previous study showed that MSCs could attenuate micro-
glial activation though secretion of the anti-inflammatory
cytokines IL-6, IL-10, and transforming growth factor beta
in LPS-induced or neurotoxin-induced animal models [11].
In addition, the present study showed that, along with in-
creased IL-10 levels after MSC treatment, MSC treatment
significantly decreased the IL-1β level in BV 2 cells and the
VEGF-A level in astrocytes that were elevated following
LPS treatment. Accordingly, the regulatory property of
microglial activation by MSCs might decrease secretion of
proinflammatory cytokines into the astrocytes and then
modulate sequentially VEGF-A-related eNOS-dependentsignaling in the endothelium, which would stabilize expres-
sion of tight junction proteins.
The consequence of BBB alteration in parkinsonian dis-
eases remains unclear. In neurodegenerative disease, neu-
rons and glia are confronted with a decreased homeostatic
reserve and thus become extremely sensitive and vulner-
able to alterations in the extracellular milieu [30]. In turn,
increased BBB permeability may increase the probability
of exposing microenvironments in the brain to environ-
mental neurotoxins, which may then interrupt mitochon-
drial electron transport or elements of the peripheral
immune system, and subsequently accelerate neuroglial
degeneration and neuroinflammation. BBB stabilization
might therefore be an effective strategy to modify disease
progression in neurodegenerative disease.
Whether impaired BBB integrity in neurodegenerative
conditions is a compensatory response to expel toxic
misfolded proteins from the brain remains unclear. Never-
theless, BBB alterations would be expected to further ac-
celerate neuroinflammation as well as neurodegeneration
[30]. Similarly, the present study showed that BBB disrup-
tion by neuroinflammation led to neutrophil infiltration in
addition to dopaminergic neuronal death. However, MSC
treatment restored activated neutrophil infiltrations and
dopaminergic neuronal death. In this regard, regardless of
the underlying response for BBB alterations, stabilizing
the BBB may represent a useful therapeutic option to pre-
vent and/or modify disease progression in PD.Conclusions
We have shown that MSCs stabilize BBB permeability
by modulating astrocytic endfeet and VEGF-A signaling,
which may be relevant as a candidate neuroprotective
strategy for the treatment of neurodegenerative disease.Additional file
Additional file 1: Figure S1. showing histological analysis of
transplanted MSCs in LPS-injected rats. The existence of MSCs in the left
SN of LPS-injected rats was identified by immunohistochemistry using
NuMA, a human specific marker (white arrow) A. The NuMA-positive cells
were observed in animals treated with human MSCs, and the number of
recruited MSCs is about 0.9 % of the total transplanted MSCs B (n = 3).
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